Global Viral Molecular Diagnostics Market Size By Type (Hepatitis B Virus (HBV), Hepatitis C Virus (HCV)), By Application (Hospitals, Academics Institutions), By Region, And Segment Forecasts, 2023 to...

The Global Viral Molecular Diagnostics Market was valued at USD 9.3 billion in 2023 and is projected to reach USD 16.7 billion by 2031, growing at a CAGR of 7.4% during the forecast period from 2023 to 2031. The market is driven by the increasing prevalence of viral infections such as HIV, hepatitis, influenza, and the continued global surveillance of emergent viruses including SARS-CoV-2 variants. Molecular diagnostics provide high sensitivity and specificity in detecting viral pathogens, enabling early intervention and improved patient outcomes. Technological advancements, coupled with growing investments in healthcare infrastructure and public health initiatives, are further boosting demand for molecular diagnostic solutions.

Drivers:

1. Growing Burden of Viral Diseases:

The global incidence of viral infections remains high, with outbreaks and re-emerging viruses necessitating rapid and accurate diagnostics. Increased screening programs and demand for point-of-care testing drive market expansion.

2. Technological Advancements in PCR and NGS:

Innovation in polymerase chain reaction (PCR), digital PCR, and next-generation sequencing (NGS) technologies has significantly improved the speed, sensitivity, and multiplexing capabilities of viral diagnostics.

3. Government and Private Sector Funding:

Heightened funding for pandemic preparedness, biothreat surveillance, and clinical diagnostics from both governmental health bodies and private organizations is fostering market growth.

Restraints:

1. High Cost of Equipment and Testing:

Despite long-term cost-efficiency, the upfront investment required for instruments and molecular assays can be prohibitive for smaller labs and in resource-constrained settings.

2. Complex Regulatory Landscape:

Lengthy and stringent regulatory approval processes for new assays and platforms can delay market entry and innovation timelines.

Opportunity:

1. Expansion in Decentralized and Home-Based Testing:

The shift toward decentralized healthcare and consumer-initiated testing presents a substantial opportunity, with rising adoption of molecular diagnostics in home and near-patient settings.

2. Application in Emerging and Re-Emerging Viruses:

Molecular diagnostics are pivotal in identifying novel and mutating viral strains, supporting epidemiological surveillance, vaccine development, and outbreak control.

Market by System Type Insights:

Based on system type, the PCR-based Diagnostics segment dominated the market in 2023 due to its widespread clinical use, cost-effectiveness, and well-established protocols. Real-time PCR is particularly favored for its rapid turnaround time and quantitative analysis capabilities. Meanwhile, NGS-based Diagnostics is expected to register the fastest growth through 2031, as the technology becomes more affordable and is adopted for comprehensive viral genome analysis, drug resistance profiling, and mutation tracking.

Market by End-use Insights:

In terms of end-use, Hospitals and Diagnostic Laboratories emerged as the leading segment in 2023, accounting for over 60% of the total market share. These institutions rely heavily on molecular diagnostics for timely and accurate viral detection. The Home Healthcare segment is projected to grow rapidly, driven by the proliferation of portable molecular devices and increasing demand for self-testing solutions for infections like influenza, COVID-19, and HPV.

Market by Regional Insights:

North America held the largest market share in 2023, owing to robust healthcare infrastructure, higher diagnostic spending, and early adoption of novel technologies. Asia-Pacific is anticipated to witness the highest growth during the forecast period, fueled by rising healthcare awareness, rapid urbanization, increased incidence of viral infections, and growing government investments in public health surveillance systems in countries such as China, India, and Japan.

Competitive Scenario:

Key players in the Global Viral Molecular Diagnostics Market include:

F. Hoffmann-La Roche Ltd.

Abbott Laboratories

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

Qiagen N.V.

Hologic, Inc.

Danaher Corporation

Seegene Inc.

Cepheid (a Danaher company)

PerkinElmer Inc.

These companies are focusing on strategic collaborations, expanding test portfolios, and integrating AI into platforms for predictive diagnostics.

Recent Developments:

In 2023, Roche launched a multiplex PCR panel for the simultaneous detection of influenza, RSV, and COVID-19.

Thermo Fisher expanded its NGS-based infectious disease testing solution globally in 2024, targeting low- and middle-income countries.

In 2025, Qiagen partnered with Microsoft Health to integrate cloud-based AI for real-time viral load monitoring.

Scope of Work – Global Viral Molecular Diagnostics Market

Report Metric Details

Market Size (2023) USD 9.3 billion

Projected Market Size (2031) USD 16.7 billion

CAGR (2023–2031) 7.4%

Market Segments By System Type (PCR, NGS, Isothermal), By End-use (Hospitals, Diagnostic Labs, Home Care), By Region

Growth Drivers Rising viral disease burden, tech innovations, funding boosts

Opportunities Decentralized testing, emerging virus surveillance

Key Market Developments:

February 2023: Bio-Rad introduced a next-gen digital PCR system enabling absolute quantification of viral RNA, targeting clinical and research